Ovid Therapeutics Inc (OVID):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ovid Therapeutics Inc (OVID) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8142
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ovid Therapeutics Inc (Ovid Therapeutics) is a bio-pharmaceutical company which identifies, discovers, and develops medicines for neurological disorders. The company’s pipeline products are indicated for diseases such as Angelman Syndrome and Fragile X Syndrome. It develops, assess, commercialize compounds and expand its product pipeline through research and development, acquisitions and combination therapies. Ovid Therapeutics works in partnership with patients, clinicians and scientists, foundations, academic centers, regulatory agencies, and companies that help the development of novel therapies. The company has collaboration with Lundbeck and Angelman Syndrome foundations. Ovid Therapeutics is headquartered in New York, the US.

Ovid Therapeutics Inc (OVID) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ovid Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ovid Therapeutics Raises USD25.8 Million in Venture Financing 11
Partnerships 12
Ovid Therapeutics and NeuroPointDX Enter into Agreement 12
Takeda Pharma and Ovid Therapeutics Enter into Agreement 13
Licensing Agreements 15
Ovid Therapeutics Enters into Licensing Agreement with Northwestern University 15
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 17
Equity Offering 18
Ovid Therapeutics Plans to Raise up to USD200 Million in Public Offering of Securities 18
Ovid Therapeutics Raises USD75 Million in IPO 19
Ovid Therapeutics Raises Funds through Private Placement 21
Ovid Therapeutics Raises USD1 Million in Second Tranche of Private Placement of Shares 23
Ovid Therapeutics Raises USD4 Million in First Tranche of Private Placement of Shares 24
Ovid Therapeutics Inc – Key Competitors 25
Ovid Therapeutics Inc – Key Employees 26
Ovid Therapeutics Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 09, 2018: Ovid Therapeutics reports second quarter 2018 financial results and highlights recent clinical progress 28
May 08, 2018: Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress 31
Mar 29, 2018: Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress 34
Nov 09, 2017: Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress 36
Aug 10, 2017: Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress 38
Jun 13, 2017: Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress 40
Corporate Communications 42
Sep 04, 2018: Dr. Yaron Werber, Chief Business and Financial Officer of Ovid Therapeutics, to Return to Wall Street 42
Jun 23, 2017: Ovid Therapeutics to be Added to Russell 2000, 3000 and Microcap Indexes 43
Jun 14, 2017: Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ovid Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ovid Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ovid Therapeutics Raises USD25.8 Million in Venture Financing 11
Ovid Therapeutics and NeuroPointDX Enter into Agreement 12
Takeda Pharma and Ovid Therapeutics Enter into Agreement 13
Ovid Therapeutics Enters into Licensing Agreement with Northwestern University 15
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 17
Ovid Therapeutics Plans to Raise up to USD200 Million in Public Offering of Securities 18
Ovid Therapeutics Raises USD75 Million in IPO 19
Ovid Therapeutics Raises Funds through Private Placement 21
Ovid Therapeutics Raises USD1 Million in Second Tranche of Private Placement of Shares 23
Ovid Therapeutics Raises USD4 Million in First Tranche of Private Placement of Shares 24
Ovid Therapeutics Inc, Key Competitors 25
Ovid Therapeutics Inc, Key Employees 26
Ovid Therapeutics Inc, Other Locations 27

List of Figures
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ovid Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Ovid Therapeutics Inc (OVID):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CEPS A.S.:企業の戦略的SWOT分析
    CEPS A.S. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Mitsui & Co., Ltd.:企業のM&A・事業提携・投資動向
    Mitsui & Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsui & Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Upstream Medical Technologies Ltd:企業の製品パイプライン分析2018
    Summary Upstream Medical Technologies Ltd (UMT) is a biomarker based testing developer that markets novel biomarkers for cardiac diagnosis. The company offers patented pipeline of products such as BNP-sp, used for diagnoses of unstable angina, CVD, ACS, and others. It provides pipe line product such …
  • Thomas & Betts Corp:企業の戦略的SWOT分析
    Thomas & Betts Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Globus Medical Inc (GMED):企業の財務・戦略的SWOT分析
    Globus Medical Inc (GMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed fo …
  • Generali France S.A.:企業の戦略・SWOT・財務分析
    Generali France S.A. - Strategy, SWOT and Corporate Finance Report Summary Generali France S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Galp Energia SGPS SA (GALP)-エネルギー分野:企業M&A・提携分析
    Summary Galp Energia SGPS S.A. (Galp Energia) is an integrated oil and natural gas company. It explores for, develops and produces crude oil and natural gas; refines crude oil and markets refined petroleum products. The company also imports, transports and distributes natural gas. It conducts the na …
  • DreamWorks Animation LLC:企業の戦略的SWOT分析
    DreamWorks Animation LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Gokul Refoils & Solvent Ltd. (GOKUL):企業の財務・戦略的SWOT分析
    Gokul Refoils & Solvent Ltd. (GOKUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • NV Bekaert SA:企業のM&A・事業提携・投資動向
    NV Bekaert SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NV Bekaert SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Energy Development Corp (EDC):企業の財務・戦略的SWOT分析
    Energy Development Corp (EDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Thai Oil Public Co Ltd (TOP):石油・ガス:M&Aディール及び事業提携情報
    Summary Thai Oil Public Company Limited (Thai Oil), a subsidiary of PTT Public Company Limited, is an integrated energy company. It is one of the largest independent petroleum refineries and suppliers of petroleum products in Thailand. It operates the largest single-site refinery in the Chonburi pro …
  • Revance Therapeutics Inc (RVNC)-医療機器分野:企業M&A・提携分析
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • Owlstone Medical Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Owlstone Medical Ltd (Owlstone Medical), formerly Tiger Dawn Ltd, is a diagnostic company. The company develops and commercializes breathalyzers for use in clinical diagnostics and precision medicines. It offers FAIMS Technology for medical applications; Lonestar for disease biomarker detect …
  • Regeneron Pharmaceuticals Inc (REGN):製薬・医療:M&Aディール及び事業提携情報
    Summary Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s six US FDA-approved medicines and product candidates in development help patients wit …
  • Celltrion Inc (068270):企業の財務・戦略的SWOT分析
    Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Par Pacific Holdings Inc (PARR):石油・ガス:M&Aディール及び事業提携情報
    Summary Par Pacific Holdings Inc (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company con …
  • Zagro Asia Ltd:企業の戦略的SWOT分析
    Zagro Asia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Nichias Corp (5393):企業の財務・戦略的SWOT分析
    Nichias Corp (5393) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆